Fluocinolone Acetonide Insert (ILUVIEN) for Diabetic Macular Edema (FAD) Study
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms FAD
- 31 Mar 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
- 31 Mar 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 28 Sep 2016 New trial record